ArticleEClinicalMedicine2024

Erythromycin for myotonic dystrophy type 1: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.

Masayuki Nakamori et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.